$KMX

Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Microsoft (NASDAQ:MSFT)

Analysts updated price targets for several companies. Piper Sandler raised Microsoft's target to $610, maintaining an Overweight rating. Other notable changes include Carmax, Accelerant, Jack Henry, Moderna, Grocery Outlet, Hinge Health, Aytu Biopharma, NetApp, and Ferrari.

Original reporting
Published Sep 30, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$KMX
Bullish
medium confidence
Mentioned
$KMX · $ARX · $JKHY · $MRNA · $GO · $HNGE
Relevance
5/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$KMXBullishLow
01

Why it matters

While the revisions provide fresh data points, they are largely reactionary and do not constitute a primary market‑moving event.

02

Market read

Analyst target updates offer modest guidance cues but lack a decisive catalyst for immediate trading decisions.

03

What to watch

Macro backdrop and upcoming earnings season could outweigh individual analyst revisions.

Relevance 5/10Novelty 5/10Timing: post‑market Tuesday

Background

The article aggregates recent analyst price‑target adjustments for a set of U.S. stocks, including Microsoft, following the latest earnings season.

Company-level read

Ticker impact

$KMXBullishMedium confidence
Context

BNP Paribas raised Carmax price target to $48, indicating potential upside.

Expected impact

likely upward pressure as investors price in higher expectations

Evidence & confidence

Analyst upgrade and higher target often precede price gains.

$ARXBearishMedium confidence
Context

TD Cowen cut Accelerant target to $20.25, indicating downside risk.

Expected impact

potential pressure as market absorbs lower expectations

Evidence & confidence

Downgrade and lower target typically lead to short-term sell pressure.

$JKHYBearishMedium confidence
Context

Morgan Stanley reduced Jack Henry target to $158, implying modest downside.

Expected impact

possible modest decline

Evidence & confidence

Analyst cut often translates to near‑term price adjustment.

$MRNANeutralLow confidence
Context

Citigroup lifted Moderna target to $80 but downgraded rating to Sell, mixed signal.

Expected impact

limited movement pending market interpretation

Evidence & confidence

Conflicting signals may offset each other.

$GOBullishMedium confidence
Context

B of A raised Grocery Outlet target to $15, indicating upside.

Expected impact

likely upward pressure

Evidence & confidence

Analyst upgrade often precedes price gains.

$HNGEBullishMedium confidence
Context

Needham raised Hinge Health target to $115, maintaining Buy rating.

Expected impact

potential upside

Evidence & confidence

Higher target aligns with bullish sentiment.

$AYTUBullishLow confidence
Context

Ascendiant Capital lifted Aytu Biopharma target to $15, modest increase.

Expected impact

minor upward pressure

Evidence & confidence

Small change may have limited market impact.

$MSFTBullishMedium confidence
Context

Piper Sandler raised Microsoft target to $610, maintaining Overweight rating.

Expected impact

potential upward pressure

Evidence & confidence

Analyst target increase for a mega‑cap often supports price gains.

Market effects

Analyst target revisions across consumer, tech, and biotech may slightly shift sector sentiment.

U.S. equity market, no specific regional effect.

Limited; primarily U.S. listed companies.

Counterpoint

Target changes may be premature; price moves could be muted if broader market sentiment dominates.

Key entities

  • Microsoft Corp

    Subject of a target raise to $610.

  • Piper Sandler

    Raised Microsoft target.

Related articles

$MRNAHighAI 8/10

Moderna (MRNA) Surges 37% in September Despite Healthcare Sector

Moderna (MRNA) surged 37.22% in September due to promising Phase 3 results for its personalized mRNA cancer vaccine, outperforming the broader healthcare sector. The company's P/S ratio is 33.44, significantly higher than its historical median of 8.41, reflecting high growth expectations. Moderna remains unprofitable, with a GF Score of 54/100, indicating mixed financial health. Insider activity shows significant selling, while guru ownership is mixed.

$NVDAHighAI 8/10

Tech giants' AI boom faces a rising cash-flow test

Nvidia, Microsoft, and Micron reported strong AI-driven revenue growth. Nvidia's Q2 revenue rose 106% YoY to $96.2B, Microsoft's Q4 revenue increased 18% YoY to $90.0B, and Micron's Q4 revenue surged 379% YoY to $54.23B. However, capital expenditures grew faster than operating cash flow, raising questions about future returns.

$MSFTLow

LinkedIn CEO Ryan Roslansky To Exit Microsoft In 2026

LinkedIn CEO Ryan Roslansky will leave Microsoft at the end of 2026, according to a memo from Microsoft CEO Satya Nadella. Roslansky, who joined LinkedIn in 2009 and became CEO in 2020, oversaw membership growth to 1.3 billion. His departure follows a leadership transition, with COO Dan Shapero now leading LinkedIn. Roslansky cited family life in the Bay Area as a factor in his decision, as the role would require relocation to Redmond, Washington.

$NTAPHigh

Why Is NetApp (NTAP) Stock Rocketing Higher Today

NetApp (NTAP) shares rose 6% after unveiling new AI factory architecture, sovereign cloud storage, and expanded partnerships. Analysts raised price targets, citing AI storage potential. The stock is up 113% YTD, hitting a 52-week high of $226.50. Revenue grew 12.5% YoY to $1.95B in Q1 2026, beating estimates, with strong guidance.

$AMZNMed

Amazon, Microsoft Face New Legal Roadblock

EU officials are considering designating Amazon's AWS and Microsoft's Azure as gatekeepers under the Digital Markets Act, potentially forcing changes to their cloud services. The European Commission argues that their market position justifies designation, despite not meeting normal thresholds. If designated, the companies could face new requirements to improve interoperability and reduce switching barriers.

$ORCLMed

Oracle Stocks Jump 2% as NetApp Storage Targets AI Migration

Oracle (ORCL) shares rose 2% to $140.88 after announcing a managed NetApp storage service on its cloud infrastructure, aiming to ease data migration for companies. The service, set for general availability in 12 months, integrates NetApp's ONTAP capabilities. Oracle is 27.3% below its GF Value estimate, indicating potential upside if the strategy succeeds.